is an early stage company focused on providing devices that unlock the potential of tear fluid for medical diagnostics

Human tears contain at least 2000 types of proteins, 600 species of lipids and 100 small molecule metabolites. Many of these constituents are promising biomarkers of systemic diseases such as dry eye disease, cystic fibrosis, multiple sclerosis, breast cancer and Alzheimer’s disease.

Despite having broad diagnostic applications, tears remain underutilized as a diagnostic biofluid mainly because tear samples are extremely difficult to collect in large enough quantities to be clinically useful. TearDx innovations aim to solve problems by giving clinicians an easy-to-apply, noninvasive method of analyzing specific biomarkers in tear fluid.

The TearDx Vision

To give clinicians simple, convenient, reliable tools to perform routine tear diagnostics

The TearDx Platform

We are developing an easily inserted wearable ocular device that analyzes specific biomarkers in tear fluid

Key Advantages

  • The device is easy to insert
  • Causes little to no discomfort to patients
  • Removes the burden of tear collection from clinicians
  • Greatly simplifies sample prep and lab analysis

The TearDx Team

Eugene Orloff